From genomics to surveillance, prevention and control: New challenges for the African meningitis belt

Vaccine ◽  
2006 ◽  
Vol 24 (20) ◽  
pp. 4279-4284 ◽  
Author(s):  
Jean-Michel Alonso ◽  
Eric Bertherat ◽  
William Perea ◽  
Ray Borrow ◽  
Suzanne Chanteau ◽  
...  
Keyword(s):  
Prevention And Control ◽  
Meningitis Belt ◽  
New Challenges ◽  
And Control

scholarly journals Semi-Synthesis of Marine-Derived Ilamycin F Derivatives and Their Antitubercular Activities

2021 ◽  
Vol 9 ◽  
Author(s):  
Jun Li ◽  
Zhiyong Liu ◽  
Mingye Hong ◽  
Changli Sun ◽  
Tianyu Zhang ◽  
...  
Keyword(s):  
Prevention And Control ◽  
Inhibitory Concentration ◽  
Drug Resistant ◽  
Structure Activity ◽  
The World ◽  
Resistant Strains ◽  
New Challenges ◽  
Low Cytotoxicity ◽  
Drug Resistant Strains ◽  
And Control

Tuberculosis (TB) is still a global disease threatening people’s lives. With the emergence of multi-drug-resistant Mycobacterium tuberculosis the prevention and control of tuberculosis faces new challenges, and the burden of tuberculosis treatment is increasing among the world. Ilamycins are novel cyclopeptides with potent anti-TB activities, which have a unique target protein against M. tuberculosis and drug-resistant strains. Herein, ilamycin F, a major secondary metabolite isolated from the marine-derived mutant strain Streptomyces atratus SCSIO ZH16 ΔilaR, is used as a scaffold to semi-synthesize eighteen new ilamycin derivatives (ilamycin NJL1–NJL18, 1–18). Our study reveals that four of ilamycin NJLs (1, 6, 8, and 10) have slightly stronger anti-TB activities against Mtb H37Rv (minimum inhibitory concentration, 1.6–1.7 μM) compared with that of ilamycin F on day 14th, but obviously display more potent activities than ilamycin F on day 3rd, indicating anti-TB activities of these derivatives with fast-onset effect. In addition, cytotoxic assays show most ilamycin NJLs with low cytotoxicity except ilamycin NJL1 (1). These findings will promote the further exploration of structure-activity relationships for ilamycins and the development of anti-TB drugs.

Hepatitis A and E in South America: New Challenges Toward Prevention and Control

2017 ◽  
pp. 119-138 ◽  
Author(s):  
Marcelo Alves Pinto ◽  
Jaqueline Mendes de Oliveira ◽  
Jorge González
Keyword(s):  
South America ◽  
Prevention And Control ◽  
Hepatitis A ◽  
New Challenges ◽  
And Control

scholarly journals Eliminating Meningococcal Epidemics From the African Meningitis Belt: The Case for Advanced Prevention and Control Using Next-Generation Meningococcal Conjugate Vaccines

2019 ◽  
Vol 220 (Supplement_4) ◽  
pp. S274-S278 ◽  
Author(s):  
Mark R Alderson ◽  
F Marc LaForce ◽  
Ajoke Sobanjo-ter Meulen ◽  
Angela Hwang ◽  
Marie-Pierre Preziosi ◽  
...  
Keyword(s):  
Conjugate Vaccine ◽  
Prevention And Control ◽  
Vaccine Development ◽  
Next Generation ◽  
Meningococcal Infections ◽  
Conjugate Vaccines ◽  
Meningitis Belt ◽  
And Control ◽  
New Vaccines

AbstractThe introduction and rollout of a meningococcal serogroup A conjugate vaccine, MenAfriVac, in the African meningitis belt has eliminated serogroup A meningococcal infections for >300 million Africans. However, serogroup C, W, and X meningococci continue to circulate and have been responsible for focal epidemics in meningitis belt countries. Affordable multivalent meningococcal conjugate vaccines are being developed to prevent these non-A epidemics. This article describes the current epidemiologic situation and status of vaccine development and highlights questions to be addressed to most efficiently use these new vaccines.

Linking decision-making research and cancer prevention and control: Important themes.

2005 ◽  
Vol 24 (4, Suppl) ◽  
pp. S106-S110 ◽  
Author(s):  
Kevin D. McCaul ◽  
Ellen Peters ◽  
Wendy Nelson ◽  
Michael Stefanek
Keyword(s):  
Decision Making ◽  
Cancer Prevention ◽  
Prevention And Control ◽  
Cancer Prevention And Control ◽  
And Control
Sign in / Sign up

Export Citation Format

Share Document